These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 10030093)

  • 1. [Immunohistochemical tumor markers in infiltrating ductal breast carcinoma].
    Gallegos M; González S; León A; Claure R; Goñi I; Andrade L; Duarte I
    Rev Med Chil; 1998 Oct; 126(10):1216-23. PubMed ID: 10030093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ductal carcinoma in situ of the breast: correlation between histologic classifications and biologic markers.
    Moreno A; Lloveras B; Figueras A; Escobedo A; Ramon JM; Sierra A; Fabra A
    Mod Pathol; 1997 Nov; 10(11):1088-92. PubMed ID: 9388058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p53 in breast cancer. Its relation to histological grade, lymph-node status, hormone receptors, cell-proliferation fraction (ki-67) and c-erbB-2. Immunohistochemical study of 153 cases.
    Sirvent JJ; Salvadó MT; Santafé M; Martínez S; Brunet J; Alvaro T; Palacios J
    Histol Histopathol; 1995 Jul; 10(3):531-9. PubMed ID: 7579801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apocrine ductal carcinoma in situ of the breast: histologic classification and expression of biologic markers.
    Leal C; Henrique R; Monteiro P; Lopes C; Bento MJ; De Sousa CP; Lopes P; Olson S; Silva MD; Page DL
    Hum Pathol; 2001 May; 32(5):487-93. PubMed ID: 11381366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COX-2 expression in DCIS: correlation with VEGF, HER-2/neu, prognostic molecular markers and clinicopathological features.
    Perrone G; Santini D; Vincenzi B; Zagami M; La Cesa A; Bianchi A; Altomare V; Primavera A; Battista C; Vetrani A; Tonini G; Rabitti C
    Histopathology; 2005 May; 46(5):561-8. PubMed ID: 15842638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utility of a simplified molecular classification of tumors for predicting survival of patients with invasive ductal breast carcinoma.
    Muñoz-Díaz MM; Fernández-Aceñero MJ; Salvadores P; Schneider J
    Anticancer Res; 2009 Nov; 29(11):4727-30. PubMed ID: 20032426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation between genetic and biological aspects in primary non-metastatic breast cancers and corresponding synchronous axillary lymph node metastasis.
    D'Andrea MR; Limiti MR; Bari M; Zambenedetti P; Montagutti A; Ricci F; Pappagallo GL; Sartori D; Vinante O; Mingazzini PL
    Breast Cancer Res Treat; 2007 Mar; 101(3):279-84. PubMed ID: 16835704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activated Akt signaling pathway in invasive ductal carcinoma of the breast: correlation with HER2 overexpression.
    Park SS; Kim SW
    Oncol Rep; 2007 Jul; 18(1):139-43. PubMed ID: 17549359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. c-erbB-2, p53 protein expression and steroid hormone receptors in breast carcinomas: an immunohistochemical study.
    Yokota T; Imamura M; Teshima S; Suzuki H; Tezuka F; Kikuchi S; Kunii Y; Yamauchi H
    Anticancer Res; 1999; 19(5B):4007-12. PubMed ID: 10628345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical detection of p53 protein expression in breast cancer in young Kuwaiti women.
    Temmim L; Baker H; Sinowatz F
    Anticancer Res; 2001; 21(1B):743-8. PubMed ID: 11299837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic and predictive factors of invasive ductal breast carcinomas.
    Lialiaris TS; Georgiou G; Sivridis E; Kareli D; Tripsiannis G; Papageorgiou A; Chrisafi S; Kritsi Z; Giatromanolaki A
    J BUON; 2010; 15(1):79-88. PubMed ID: 20414932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemical co-expression of c-erbb-2/Neu oncoprotein, altered tumour suppressor (p53) protein, EGF-R and EMA in histological subtypes of infiltrating duct carcinoma of the breast.
    Sharma BK; Ray A; Kaur S; Gupta S
    Indian J Exp Biol; 1999 Mar; 37(3):223-7. PubMed ID: 10641149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TRAIL death receptor-4 expression positively correlates with the tumor grade in breast cancer patients with invasive ductal carcinoma.
    Sanlioglu AD; Korcum AF; Pestereli E; Erdogan G; Karaveli S; Savas B; Griffith TS; Sanlioglu S
    Int J Radiat Oncol Biol Phys; 2007 Nov; 69(3):716-23. PubMed ID: 17512128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mammographically-detected ductal in situ carcinoma of the breast analyzed with a new classification. A study of 127 cases: correlation with estrogen and progesterone receptors, p53 and c-erbB-2 proteins, and proliferative activity.
    Zafrani B; Leroyer A; Fourquet A; Laurent M; Trophilme D; Validire P; Sastre-Garau X
    Semin Diagn Pathol; 1994 Aug; 11(3):208-14. PubMed ID: 7831532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. C-erbB-2 expression is a better predictor for survival than galectin-3 or p53 in early-stage breast cancer.
    Logullo AF; Lopes AB; Nonogaki S; Soares FA; Netto MM; Nishimoto IN; Brentani MM
    Oncol Rep; 2007 Jul; 18(1):121-6. PubMed ID: 17549356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intraductal spread of invasive breast carcinoma has a positive correlation with c-erb B-2 overexpression and vascular invasion.
    Jing X; Kakudo K; Murakami M; Nakamura Y; Nakamura M; Yokoi T; Yang Q; Oura S; Sakurai T
    Cancer; 1999 Aug; 86(3):439-48. PubMed ID: 10430252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation of HER-2/neu protein overexpression with other prognostic and predictive factors in invasive ductal breast cancer.
    Ivkovic-Kapicl T; Knezevic-Usaj S; Djilas-Ivanovic D; Panjkovic M
    In Vivo; 2007; 21(4):673-8. PubMed ID: 17708365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Relationship of oncogene C-erbB2 expression to ER, PR and PS2 in breast cancer and its prognostic significance].
    Yang JQ; Chen L; Xing TY
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 May; 35(3):334-6, 357. PubMed ID: 15181828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concurrent overexpression of p53 and c-erbB-2 correlates with accelerated cycling and concomitant poor prognosis in node-negative breast cancer.
    Rudolph P; Alm P; Olsson H; Heidebrecht HJ; Fernö M; Baldetorp B; Parwaresch R
    Hum Pathol; 2001 Mar; 32(3):311-9. PubMed ID: 11274641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of clinical, pathological status, hormone receptor and C-erbB-2 oncoprotein in breast cancer patients.
    Aryandono T; Harijadi ; Ghozali A
    Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():600-6. PubMed ID: 10895217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.